Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer

xlomafota13 shared this article with you from Inoreader Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer Via radioactive iodine J Clin Invest. 2021 Sep 15;131(18):152696. doi: 10.1172/JCI152696. ABSTRACT Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer in the pediatric population and represents the second most common malignancy in adolescent females. Historically, PTC has been classified on the basis of histology, however, accumulating data indicate that molecular subtyping based on somatic oncogenic alterations along with gene expression profiling can better predict c linical behavior and may provide opportunities to incorporate oncogene-specific inhibitory therapy to improve the response to radioactive iodine (RAI). In this issue of the JCI, Y.A. Lee, H. Lee, and colleagues showed that oncogenic fusions were more commonly associated with invasive disease, increased expression of MAPK signaling pathway genes (ERK score), and decreased expression of the sodium-iodine symporter, which was restored by RET- and NTRK-inhibitory therapy. These findings lend credence to the idea of reclassifying pediatric thyroid cancers using a three-tiered system, rather than the two-tiered adult system, and open avenues for the treatment of progressive, RAI-refractory PTC in patients. PMID:34523607 | DOI:10.1172/JCI152696 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.